{"id":57889,"date":"2026-04-29T19:58:32","date_gmt":"2026-04-29T19:58:32","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/57889\/"},"modified":"2026-04-29T19:58:32","modified_gmt":"2026-04-29T19:58:32","slug":"wilson-sonsini-advises-foresight-on-roche-settlement-and-licensing-agreement","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/57889\/","title":{"rendered":"Wilson Sonsini Advises Foresight on Roche Settlement and Licensing Agreement"},"content":{"rendered":"<p>On August 29, 2025, Foresight Diagnostics, a privately held cancer diagnostics company and CLIA-registered laboratory, announced that it has entered into a limited licensing agreement with Roche Molecular Systems and Roche Sequencing Systems (together, Roche) involving Foresight\u2019s patented PhasED-Seq\u2122 technology. The agreement resolves litigation between the parties, with all claims against Foresight, its founders, and Stanford University dismissed with prejudice. Wilson Sonsini Goodrich &amp; Rosati advised Foresight on the settlement and licensing agreement.<\/p>\n<p>Under the agreement, Foresight granted Roche a limited, royalty-bearing, non-exclusive sublicense under certain patents for the use of PhasED-Seq for performing services and commercializing in vitro diagnostic (IVD) kits for Non-Hodgkin\u2019s Lymphoma (NHL). The patents are owned by Stanford University, and Foresight holds the exclusive license for all uses and geographies.<\/p>\n<p>The Wilson Sonsini team included <a href=\"https:\/\/www.wsgr.com\/en\/people\/ian-b-edvalson.html\" rel=\"nofollow noopener\" target=\"_blank\">Ian Edvalson<\/a>, <a href=\"https:\/\/www.wsgr.com\/en\/people\/maya-skubatch.html\" rel=\"nofollow noopener\" target=\"_blank\">Maya Skubatch<\/a>, <a href=\"https:\/\/www.wsgr.com\/en\/people\/nguyen-t-pham.html\" rel=\"nofollow noopener\" target=\"_blank\">Nguyen Pham<\/a>, and <a href=\"https:\/\/www.wsgr.com\/en\/people\/rex-w-watkins.html\" rel=\"nofollow noopener\" target=\"_blank\">Rex Watkins<\/a>.<\/p>\n<p>For more information, please see Foresight Diagnostics\u2019 <a href=\"https:\/\/foresight-dx.com\/press_releases\/foresight-diagnostics-and-roche-enter-licensing-agreement-for-phased-seq-technology-in-non-hodgkins-lymphoma\/\" rel=\"nofollow noopener\" target=\"_blank\">press release<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"On August 29, 2025, Foresight Diagnostics, a privately held cancer diagnostics company and CLIA-registered laboratory, announced that it&hellip;\n","protected":false},"author":2,"featured_media":57890,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[1766,23177,32183,32148,29033,32147,32194,12868,12040,114,32184,32195,3033,32149,351,30645,22278,32150,32152,32151,12480,32153,32169,32168,2593,32174,32185,32186,31076,32155,32170,32172,393,32156,32154,32175,32171,32145,32178,3260,32179,22500,32158,272,32159,32160,32157,10006,67,32167,1245,1831,1723,32180,1339,32161,3343,32181,2521,3984,18294,9157,3708,32187,32189,32176,32177,32162,173,32190,32163,22227,134,32146,32198,7664,32197,32173,32182,1688,5067,4770,32144,12745,178,32191,32164,1595,32188,32192,32165,17503,8630,23849,32193,2748,32139,32196,2759,32199,245,32166,32143,32141,32142,32140],"class_list":["post-57889","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-acquisitions","tag-antitrust","tag-antitrust-analysis","tag-antitrust-law","tag-attorney","tag-attornies","tag-austin","tag-belgium","tag-brussels","tag-business","tag-business-realignment","tag-ca","tag-california","tag-charitable-planning","tag-china","tag-class-action","tag-class-actions","tag-clean-tech","tag-clean-technology","tag-cleantech","tag-compensation","tag-consumer-regulatory-privacy","tag-corporate-securities","tag-corporate-and-securities","tag-data-security","tag-debt-offerings","tag-domestic","tag-early-public-companies","tag-employee-benefits","tag-employee-benefits-counseling","tag-employee-law","tag-employment-law","tag-energy","tag-energy-clean-technology","tag-environmental","tag-equity-public-offering","tag-equity-public-offerings","tag-goodrich","tag-hart-scott-rodino-filings","tag-hong-kong","tag-hsr-filings","tag-intellectual-property","tag-intellectual-property-litigation","tag-international","tag-internet-law","tag-investment-funds","tag-ip","tag-ipo","tag-law","tag-leading-law-firm","tag-legal","tag-life-sciences","tag-litigation","tag-m-a-transactions","tag-merger","tag-merger-and-acquisitions","tag-mergers-and-acquisitions","tag-mergers-and-acquisitions-transactions","tag-new-york","tag-new-york-city","tag-ny","tag-palo-alto","tag-patents","tag-patents-and-trademarks","tag-public-companies","tag-public-offering","tag-public-offerings","tag-qualified-retirement-plans","tag-real-estate","tag-real-estate-and-environmental","tag-retirement-plan","tag-retirement-plans","tag-roche","tag-rosati","tag-san-fran","tag-san-francisco","tag-seattle","tag-securities-class-action-filings","tag-securities-fraud","tag-securities-litigation","tag-shanghai","tag-silicon-valley","tag-sonsini","tag-start-ups","tag-tax","tag-technology-licensing","tag-technology-transactions","tag-texas","tag-trademark","tag-trademarks","tag-trust-and-estate-planning","tag-tx","tag-venture","tag-venture-capital","tag-venture-capital-fund","tag-virginia","tag-w-s-g-r","tag-wa","tag-washington","tag-washington-state","tag-wealth-management","tag-welfare-benefits","tag-wilson","tag-wilson-sonsini-goodrich-rosati","tag-wilson-sonsini-goodrich-and-rosati","tag-wsgr"],"share_on_mastodon":{"url":"","error":"Validation failed: Text character limit of 500 exceeded"},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/57889","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=57889"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/57889\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/57890"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=57889"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=57889"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=57889"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}